Drug Profile
Hydroxypropyl beta cyclodextrin adjuvanted influenza split vaccine - Daiichi Sankyo Biotech
Alternative Names: HP-beta-CyD-adjuvanted influenza split vaccineLatest Information Update: 28 Nov 2020
Price :
$50
*
At a glance
- Originator Kitasato Daiichi Sankyo Vaccine
- Developer Daiichi Sankyo Biotech
- Class Antivirals
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for phase-I development in Influenza-virus-infections in Japan (SC)
- 30 Nov 2017 Kitasato Daiichi Sankyo Vaccine has been acquired by Daiichi Sankyo Company
- 08 Sep 2017 Kitasato-Daiichi Sankyo Vaccine plans a phase I trial for Influenza virus infections (Prevention) in Japan (SC) (UMIN000028530)